NCT06095791View on ClinicalTrials.gov

Identification of Immunomodulators Associated With Atrial Fibrillation Reporting: Analysis of the WHO Pharmacovigilance Database

CompletedOBSERVATIONAL

Enrollment

4,000,000

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

September 1, 2022

Study Completion Date

September 1, 2022

Conditions

Atrial Fibrillation

Interventions

DRUG

Immunomodulators with FDA approval on the 1st January 2023.

Disproportionnality analysis studying the association between immunomodulators with FDA approval on the 1st January 2023 and atrial fibrillation in the World Health Organization pharmacovigilance database.

Trial Locations (1)

14000

Alexandre Joachim, Caen

All Listed Sponsors

lead

University Hospital, Caen

OTHER